La vitamine D au secours du traumatisme médullaire : un espoir à confirmer

Accès gratuit

Numéro		Biologie Aujourd'hui Volume 208, Numéro 1, 2014


Page(s)		69 - 75
Section		La vitamine D, une hormone stéroïde méconnue
DOI		https://doi.org/10.1051/jbio/2014008
Publié en ligne		23 juin 2014

Ali M.M., Vaidya V., Vitamin D and cancer. J Cancer Res Ther, 2007, 3, 225–230. [CrossRef] [PubMed] [Google Scholar]
Alroy I., Towers T.L., Freedman L.P., Transcriptional repression of the interleukin-2 gene by vitamin D₃: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol, 1995, 15, 5789–5799. [PubMed] [Google Scholar]
Bianco J., Gueye Y., Marqueste T., Alluin O., Risso J.J., Garcia S., Lavault M.N., Khrestchatisky M., Féron F., Decherchi P., Vitamin D(3) improves respiratory adjustment to fatigue and H-reflex responses in paraplegic adult rats. Neuroscience, 2011, 188, 182–192. [CrossRef] [PubMed] [Google Scholar]
Brown J., Bianco J.I., McGrath J.J., Eyles D.W., 1,25-dihydroxyvitamin D₃ induces nerve growth factor, promotes neurite outgrowth and inhibits mitosis in embryonic rat hippocampal neurons. Neurosci Lett, 2003, 343, 139–143. [CrossRef] [PubMed] [Google Scholar]
Cantorna M.T., Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol, 2006, 92, 60–64. [CrossRef] [PubMed] [Google Scholar]
Cantorna M.T., Hayes C.E., DeLuca H.F., 1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr, 1998a, 128, 68–72. [PubMed] [Google Scholar]
Cantorna M.T., Woodward W.D., Hayes C.E., DeLuca H.F., 1,25-dihydroxyvitamin D₃ is a positive regulator for the two anti-encephalitogenic cytokines TGF-beta 1 and IL-4. J Immunol, 1998b, 160, 5314–5319. [PubMed] [Google Scholar]
Chabas J.F., Alluin O., Rao G., Garcia S., Lavaut M.N., Risso J.J., Legré R., Magalon G., Khrestchatisky M., Marqueste T., Decherchi P., Féron F., Vitamin D₂ potentiates axon regeneration. J Neurotrauma, 2008, 25, 1247–1256. [CrossRef] [PubMed] [Google Scholar]
Chabas J.F., Stephan D., Marqueste T., Garcia S., Lavaut M.N., Nguyen C., Legré R., Khrestchatisky M., Decherchi P., Féron F., Cholecalciferol (vitamin D(3)) improves myelination and recovery after nerve injury. PLoS One, 2013, 8, e65034. [CrossRef] [PubMed] [Google Scholar]
Chen T.C., Wang L., Whitlatch L.W., Flanagan J.N., Holick M.F., Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J Cell Biochem, 2003, 88, 315–322. [CrossRef] [PubMed] [Google Scholar]
Christakos S., Raval-Pandya M., Wernyj R.P., Yang W., Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D₃. Biochem J, 1996, 316 (Pt 2), 361–371. [PubMed] [Google Scholar]
Cippitelli M., Santoni A., Vitamin D₃: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol, 1998, 28, 3017–3030. [CrossRef] [PubMed] [Google Scholar]
Cornet A., Baudet C., Neveu I., Baron-Van Evercooren A., Brachet P., Naveilhan P., 1,25-Dihydroxyvitamin D₃ regulates the expression of VDR and NGF gene in Schwann cells in vitro. J Neurosci Res, 1998, 53, 742–746. [CrossRef] [PubMed] [Google Scholar]
Decherchi P., Dousset E., Jammes Y., Respiratory and cardiovascular responses evoked by tibialis anterior muscle afferent fibers in rats. Exp Brain Res, 2007, 183, 299–312. [CrossRef] [PubMed] [Google Scholar]
Deeb K.K., Trump D.L., Johnson C.S., Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer, 2007, 7, 684–700. [CrossRef] [PubMed] [Google Scholar]
Eyles D., Brown J., Mackay-Sim A., McGrath J., Féron F., Vitamin D₃ and brain development. Neuroscience, 2003, 118, 641–653. [CrossRef] [PubMed] [Google Scholar]
Eyles D.W., Smith S., Kinobe R., Hewison M., McGrath J.J., Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 2005, 29, 21–30. [CrossRef] [PubMed] [Google Scholar]
Fernandes de Abreu D.A., Eyles D., Féron F., Vitamin D, a neuro-immunomodulator: implications for brain and autoimmune diseases. Psychoneuroendocrinology, 2009, 34S: 265–277. [CrossRef] [Google Scholar]
Fernandes de Abreu D.A., Landel V., Féron F., Seasonal, gestational and postnatal influences on multiple sclerosis: The beneficial role of a vitamin D supplementation during early life. J Neurol Sci, 2011, 311, 64–68. [CrossRef] [PubMed] [Google Scholar]
Fu G.K., Lin D., Zhang M.Y., Bikle D.D., Shackleton C.H., Miller W.L., Portale A.A., Cloning of human 25-hydroxyvitamin D-1 alpha-hydroxylase and mutations causing vitamin D-dependent rickets type 1. Mol Endocrinol, 1997, 11, 1961–1970. [PubMed] [Google Scholar]
Garcion E., Thanh X.D., Bled F., Teissier E., Dehouck M.P., Rigault F., Brachet P., Girault A., Torpier G., Darcy F., 1,25-Dihydroxyvitamin D₃ regulates gamma 1 transpeptidase activity in rat brain. Neurosci Lett, 1996, 216, 183–186. [CrossRef] [PubMed] [Google Scholar]
Griffin M.D., Lutz W., Phan V.A., Bachman L.A., McKean D.J., Kumar R., Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D₃ and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA, 2001, 98, 6800–6805. [CrossRef] [Google Scholar]
Hakim I., Bar-Shavit Z., Modulation of TNF-alpha expression in bone marrow macrophages: involvement of vitamin D response element. J Cell Biochem, 2003, 88, 986–998. [CrossRef] [PubMed] [Google Scholar]
Hannah S.S., Norman A.W., 1 alpha,25(OH)2 vitamin D₃-regulated expression of the eukaryotic genome. Nutr Rev, 1994, 52, 376–382. [CrossRef] [PubMed] [Google Scholar]
Lemire J.M., Archer D.C., 1,25-dihydroxyvitamin D₃ prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest, 1991, 87, 1103–1107. [CrossRef] [PubMed] [Google Scholar]
Mathieu C., Adorini L., The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med, 2002, 8, 174–179. [CrossRef] [PubMed] [Google Scholar]
Mathieu C., Decallonne B., van Etten E., [1,25-dihydroxyvitamin D₃: the endocrine system meets the immune system]. Verh K Acad Geneeskd Belg, 2002, 64, 71-80; discussion 80–72. [PubMed] [Google Scholar]
Matsumoto K., Hashimoto K., Kiyoki M., Yamamoto M., Yoshikawa K., Effect of 1,24R-dihydroxyvitamin D₃ on the growth of human keratinocytes. J Dermatol, 1990a, 17, 97–103. [PubMed] [Google Scholar]
Matsumoto K., Hashimoto K., Nishida Y., Hashiro M., Yoshikawa K., Growth-inhibitory effects of 1,25-dihydroxyvitamin D₃ on normal human keratinocytes cultured in serum-free medium. Biochem Biophys Res Commun, 1990b, 166, 916–923. [CrossRef] [PubMed] [Google Scholar]
Nagpal S., Na S., Rathnachalam R., Noncalcemic actions of vitamin D receptor ligands. Endocr Rev, 2005, 26, 662–687. [CrossRef] [PubMed] [Google Scholar]
Neveu I., Naveilhan P., Baudet C., Brachet P., Metsis M., 1,25-dihydroxyvitamin D₃ regulates NT-3, NT-4 but not BDNF mRNA in astrocytes. Neuroreport, 1994a, 6, 124–126. [CrossRef] [PubMed] [Google Scholar]
Neveu I., Naveilhan P., Jehan F., Baudet C., Wion D., De Luca H.F., Brachet P., 1,25-dihydroxyvitamin D₃ regulates the synthesis of nerve growth factor in primary cultures of glial cells. Brain Res Mol Brain Res, 1994b, 24, 70–76. [CrossRef] [PubMed] [Google Scholar]
Omdahl J.L., Morris H.A., May B.K., Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr, 2002, 22, 139–166. [CrossRef] [PubMed] [Google Scholar]
Penna G., Adorini L., Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D(3). Transplant Proc, 2001, 33, 2083–2084. [CrossRef] [PubMed] [Google Scholar]
Taniura H., Ito M., Sanada N., Kuramoto N., Ohno Y., Nakamichi N., Yoneda Y., Chronic vitamin D₃ treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res, 2006, 83, 1179–1189. [CrossRef] [PubMed] [Google Scholar]
Trump D.L., Hershberger P.A., Bernardi R.J., Ahmed S., Muindi J., Fakih M., Yu W.D., Johnson C.S., Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol, 2004, 89–90, 519−526. [CrossRef] [PubMed] [Google Scholar]
van de Kerkhof P.C., Reduction of epidermal abnormalities and inflammatory changes in psoriatic plaques during treatment with vitamin D₃ analogs. J Investig Dermatol Symp Proc, 1996, 1, 78–81. [PubMed] [Google Scholar]
Wang T.T., Tavera-Mendoza L.E., Laperrière D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H., Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D₃ target genes. Mol Endocrinol, 2005, 19, 2685–2695. [CrossRef] [PubMed] [Google Scholar]
Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., Hewison M., Extrarenal expression of 25-hydroxyvitamin D(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab, 2001, 86, 888–894. [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.